Item 6. EXHIBITS

Exhibits (listed by number corresponding to the Exhibit Table of Item 601 in Regulation S-K).


Exhibit No.						Description
4a.						Fifteenth Supplemental Indenture, dated as of February 22, 2024, by and between Bristol-Myers Squibb Company and The Bank of New York Mellon, as Trustee, to the Indenture dated as of June 1, 1993 (incorporate d herein by reference to Exhi bit 4.1 to the Form 8-K dated and filed on February 22, 2024).
4b.						Form of $500,000,000 Floating Rate Notes due 2026 (incorporated herein by reference to Exhibit 4.2 to the Form 8-K dated and filed on February 22, 2024).
4c.						Form of $1,000,000,000 4.950% Notes due 2026 (incorporated herein by reference to Exhibit 4.3 to the Form 8-K dated and filed on February 22, 2024).
4d.						Form of $1,000,000,000 4.900% Notes due 2027 (incorporated herein by reference to Exhibit 4.4 to the Form 8-K dated and filed on February 22, 2024).
4e.						Form of $1,750,000,000 4.900% Notes due 2029 (incorporated herein by reference to Exhibit 4.5 to the Form 8-K dated and filed on February 22, 2024).
4f.						Form of $1,250,000,000 5.100% Notes due 2031 (incorporated herein by reference to Exhibit 4.6 to the Form 8-K dated and filed on February 22, 2024).
4g.						Form of $2,500,000,000 5.200% Notes due 2034 (incorporated herein by reference to Exhibit 4.7 to the Form 8-K dated and filed on February 22, 2024).
4h.						Form of $500,000,000 5.500% Notes due 2044 (incorporated herein by reference to Exhibit 4.8 to the Form 8-K dated and filed on February 22, 2024).
4i.						Form of $2,750,000,000 5.550% Notes due 2054 (incorporated herein by reference to Exhibit 4.9 to the Form 8-K dated and filed on February 22, 2024).
4j.						Form of $1,750,000,000 5.650% Notes due 2064 (incorporated herein by reference to Exhibit 4.10 to the Form 8-K dated and filed on February 22, 2024).
31a.						Section 302 Certification Letter.
31b.						Section 302 Certification Letter.
32a.						Section 906 Certification Letter.
32b.						Section 906 Certification Letter.
101.INS						XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH						XBRL Taxonomy Extension Schema Document.
101.CAL						XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF						XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB						XBRL Taxonomy Extension Label Linkbase Document.
101.PRE						XBRL Taxonomy Extension Presentation Linkbase Document.
104						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

Indicates, in this Quarterly Report on Form 10-Q, brand names of products, which are registered trademarks not solely owned by the Company or its subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd.; Gleevec is a trademark of Novartis AG; Keytruda is a trademark of Merck Sharp & Dohme Corp; Onglyza is a trademark of AstraZeneca AB; Otezla is a trademark of Amgen Inc.; Plavix is a trademark of Sanofi; and Tecentriq is a trademark of Genentech, Inc. Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of BMS and/or one of its subsidiaries.

SUMMARY OF ABBREVIATED TERMS

Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this Quarterly Report on Form 10-Q, unless the context otherwise indicates. Throughout this Quarterly Report on Form 10-Q we have used terms which are defined below:


2023 Form 10-K	Annual Report on Form 10-K for the fiscal year ended December 31, 2023	Mirati	Mirati Therapeutics, Inc.
2024 Senior Unsecured Notes	Aggregate principal amount of $13.0 billion of unsecured senior notes issued by BMS in February 2024	MPM	malignant pleural mesothelioma
aGVHD	acute graft-versus-host disease	NKT	natural killer T cells
ANDA	Abbreviated New Drug Application	NDA	New Drug Application
AstraZeneca	AstraZeneca PLC	NSCLC	non-small cell lung cancer
BCMA	B-cell maturation antigen-directed	Nimbus	Nimbus Therapeutics
CAR-T	chimeric antigen receptor T-cell	NVAF	non-valvular atrial fibrillation
Celgene	Celgene Corporation	OECD	Organization for Economic Co-operation and Development
CERCLA	U.S. Comprehensive Environmental Response, Compensation and Liability Act	Ono	Ono Pharmaceutical Co., Ltd
CGDP	Coverage Gap Discount Program	Otsuka	Otsuka Pharmaceutical Co., Ltd.
CML	chronic myeloid leukemia	PD-1	programmed cell death protein 1
CRC	colorectal carcinoma	PD-L1	programmed death-ligand 1
EC	European Commission	PDUFA	Prescription Drug User Fee Act
EPS	earnings per share	PsA	psoriatic arthritis
ESA	erythropoiesis stimulating agent	Quarterly Report on Form 10-Q	Quarterly Report on Form 10-Q for the quarter ended March 31, 2024
EU	European Union	R&D	research and development
Exchange Act	the Securities Exchange Act of 1934	RA	rheumatoid arthritis
FDA	U.S. Food and Drug Administration	RayzeBio	RayzeBio, Inc.
FL	follicular lymphoma	RCC	renal cell carcinoma
GAAP	generally accepted accounting principles	REMS	risk evaluation and mitigation strategy
GTN	gross-to-net	Sanofi	Sanofi S.A.
HCC	hepatocellular carcinoma	SEC	U.S. Securities and Exchange Commission
HCM	hypertrophic cardiomyopathy	Section 174	Guidance on amortization of specified research or experimental expenditures under Section 174 Notice 2023-63
IMDC	International Metastatic - Renal Cell Carcinoma Database Consortium	sNDA	Supplemental New Drug Application
IPRD	in-process research and development	SPC	Supplementary Protection Certificate
IRA	Inflation Reduction Act of 2022	SystImmune	SystImmune, Inc.
IRS	Internal Revenue Service	Takeda	Takeda Pharmaceutical Company Limited
IV	intravenous	Turning Point	Turning Point Therapeutics, Inc.
JIA	juvenile idiopathic arthritis	UC	ulcerative colitis
Juno	Juno Therapeutics, Inc.	UK	United Kingdom
Karuna	Karuna Therapeutics, Inc.	U.S.	United States
MDL	multi-district litigation	USPTO	U.S. Patent and Trademark Office
MDS	myelodysplastic syndromes	VAT	value added tax
Merck	Merck & Co.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		BRISTOL-MYERS SQUIBB COMPANY (REGISTRANT)

Date:	April 25, 2024	By:	/s/ Christopher Boerner, Ph.D.
			Christopher Boerner, Ph. D. Chairman of the Board and Chief Executive Officer

Date:	April 25, 2024	By:	/s/ David V. Elkins
			David V. Elkins Chief Financial Officer

Previous: Item 5. OTHER INFORMATION